Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Beatrice Fournier"'
Autor:
Matthias Preusser, Tomáš Kazda, Emilie Le Rhun, Felix Sahm, Marion Smits, Jens Gempt, Johan AF Koekkoek, Angelo F Monti, Marcell Csanadi, János György Pitter, Helen Bulbek, Beatrice Fournier, Caroline Quoilin, Thierry Gorlia, Michael Weller, Giuseppe Minniti, on behalf of the European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known. Methods EORTC-2227-BTG (LEGATO, NCT05904119) is
Externí odkaz:
https://doaj.org/article/da487c7b1214453fb930ea4fb6b04a3a
Autor:
Piet Ost, Coen W. Hurkmans, Nandita M. deSouza, Yolande Lievens, Icro Meattini, Bertrand Tombal, Dirk Verellen, Daniel Schanne, Christine Verfaillie, Alejandra Méndez Romero, Beatrice Fournier, Umberto Ricardi, Frédéric Lecouvet, Andre Dekker, Laurence Collette, Nicola S. Russell, Matthias Guckenberger, Marta Scorsetti, Angelique B Bouma, Anne-Marie C. Dingemans
Publikováno v:
The lancet oncology
Lancet Oncology, 21(1), E18-E28. Lancet Publishing Group
The Lancet Oncology, Vol. 21, no. 1, p. e18-e28 (2020)
Lancet Oncology, 21(1), E18-E28. Lancet Publishing Group
The Lancet Oncology, Vol. 21, no. 1, p. e18-e28 (2020)
Oligometastatic disease has been proposed as an intermediate state between localised and systemically metastasised disease. In the absence of randomised phase 3 trials, early clinical studies show improved survival when radical local therapy is added
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b351b259335b0e3e14d339bb4eaa7d
https://doi.org/10.1016/s1470-2045(19)30718-1
https://doi.org/10.1016/s1470-2045(19)30718-1
Autor:
Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, Fernando López-Campos, Piet Ost, Thierry Andre Roumeguere, Bernardo Herrera-Imbroda, Lionel A. D'Hondt, Magali Quivrin, Paolo Gontero, Salvador Villà, Hussein Mustafa Khaled, Beatrice Fournier, Joanna Krzystyniak, Yassin Pretzenbacher, Hazal Erkol, Yohann Loriot
Publikováno v:
Journal of Clinical Oncology. 41:160-160
160 Background: Darolutamide is androgen-receptor (AR) inhibitor with low blood–brain barrier penetration and limited potential for clinically relevant drug–drug interactions. Darolutamide has been shown to increase overall survival in combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8610616974d2df83f12a0351b0a2e58
https://doi.org/10.1200/jco.2023.41.6_suppl.160
https://doi.org/10.1200/jco.2023.41.6_suppl.160
Autor:
Warren Sateren, Mary-Ann Dalzell, Beatrice Fournier, Petr Kavan, Marize Ibrahim, Richard Dalfen, Thierry Muanza, Michael Palumbo, Nadia Smirnow
Publikováno v:
Clinical Breast Cancer. 18:e55-e64
Background The diagnosis of breast cancer in young women (aged 18-45 years) has been increasing. Women are commonly left coping with treatment-related disabilities of the upper limb that can persist for > 2 years postoperatively. Patients and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21a4dff7bb28c2b9356b9cfe05d5b18
https://doi.org/10.1016/j.clbc.2017.06.007
https://doi.org/10.1016/j.clbc.2017.06.007
Autor:
Guillaume Grisay, Fabio Turco, Saskia Litiere, Béatrice Fournier, Anna Patrikidou, Enrique Gallardo, Ray McDermott, Ahu Alanya, Silke Gillessen, Bertrand Tombal
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation Therapy (ADT), significantly improving survival rates. However, prolonged use of these therapies
Externí odkaz:
https://doaj.org/article/81835467e73e4364af4a30938a8d05b9
Autor:
Franco Nolè, Silke Gillessen, Yohann Loriot, Alejo Rodriguez-Vida, Raymond S. McDermott, Fred Saad, Bertrand F. Tombal, T. Roumeguere, Gedske Daugaard, Anouk Neven, Beatrice Fournier, Ananya Choudhury, Enrique Gallardo Diaz
Publikováno v:
Journal of Clinical Oncology. 39:5002-5002
5002 Background: The randomized phase III EORTC-1333-GUCG (NCT02194842) trial compares enzalutamide vs. a combination of Radium 223 and enzalutamide in asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::735346815453de96abcd45f08a49ca86
https://doi.org/10.1200/jco.2021.39.15_suppl.5002
https://doi.org/10.1200/jco.2021.39.15_suppl.5002
Autor:
Patrick Roth, Jaap Reijneveld, Thierry Gorlia, Frederic Dhermain, Maureen Vanlancker, Beatrice Fournier, Sarah Nuyens, Chris O’Callaghan, Emilie Le Rhun, Ileana Elias, Martin van den Bent, Warren Mason, Benjamin Winograd, Michael Weller
BACKGROUND: The standard of care for patients with newly diagnosed glioblastoma includes maximum safe surgery, involved-field radiotherapy (RT), and concomitant and up to six cycles of maintenance temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c96a01e2642dcf3a6312689e260922d
https://europepmc.org/articles/PMC6217655/
https://europepmc.org/articles/PMC6217655/
Autor:
Warren Sateren, Nadia Smirnow, Michael Palumbo, Beatrice Fournier, Marize Ibrahim, Mary-Ann Dalzell, Richard Dalfen, Petr Kavan, Thierry Muanza
Publikováno v:
Journal of cancer survivorship : research and practice. 11(6)
Breast cancer (BC) diagnosis in young adults (YA) is rising, and both disease and treatments are aggressive in this population. Evidence supports the use of physical activity in reducing shoulder dysfunction, which is common among BC survivors. A pil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0ee84d1b48ad020cab3a2d31f9ac5d
https://pubmed.ncbi.nlm.nih.gov/28470507
https://pubmed.ncbi.nlm.nih.gov/28470507
Publikováno v:
Neuro-Oncology. 20:vi23-vi24
BACKGROUND: TG02 is an oral multi-cyclin dependent kinase (CDK) inhibitor that is thought to inhibit tumor growth mainly through CDK9-dependent depletion of oncoproteins such as MCL-1 and MYC. MCL-1 and MYC are frequently overexpressed in glioblastom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fbdd225f0d59621b6a5a1661071ce95
https://doi.org/10.1093/neuonc/noy148.085
https://doi.org/10.1093/neuonc/noy148.085
Autor:
Fred Saad, Laurence Collette, Tony Elliott, Franco Nolè, Silke Gillessen, Alejo Rodriguez-Vida, Bertrand F. Tombal, Yohann Loriot, Beatrice Fournier, Raymond S. McDermott
Publikováno v:
Journal of Clinical Oncology. 37:5007-5007
5007 Background: Skeletal fractures, pathological or not, are a frequent and underestimated side-effect of systemic treatment of metastatic castration resistant prostate cancer (mCRPC). The ERA223 trial (NCT02043678) was recently unblinded following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b17e5e65017d07b9556ae724ddadd517
https://doi.org/10.1200/jco.2019.37.15_suppl.5007
https://doi.org/10.1200/jco.2019.37.15_suppl.5007